Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells

American Cancer Society, 2008 Ye, 2007, Biology and clinical management of prostate cancer bone metastasis, Front Biosci, 12, 3273, 10.2741/2311 Clines, 2008, Molecular mechanisms and treatment of bone metastasis, Expert Rev Mol Med, 10, e7, 10.1017/S1462399408000616 Boyd, 1995, Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen, Drug Dev Res, 34, 91, 10.1002/ddr.430340203 Shoemaker, 2006, The NCI60 human tumour cell line anticancer drug screen, Nat Rev Cancer, 6, 813, 10.1038/nrc1951 Thalmann, 2000, LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis, Prostate, 44, 91, 10.1002/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L Cragg, 2004, A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy, J Nat Prod, 67, 232, 10.1021/np030420c Dosso, 2008, Docetaxel in the management of prostate cancer: current standard of care and future directions, Expert Opin Pharmacother, 9, 1969, 10.1517/14656566.9.11.1969 Abraham, 2007, The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy, Clin Cancer Res, 13, 3109, 10.1158/1078-0432.CCR-06-2798 Brown, 2004 Qiu, 2008, Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes, J Control Release, 129, 144, 10.1016/j.jconrel.2008.04.019 Simamora, 2001, Solubilization of rapamycin, Int J Pharm, 213, 25, 10.1016/S0378-5173(00)00617-7 Fischbach, 2007, Engineering tumors with 3D scaffolds, Nat Methods, 4, 855, 10.1038/nmeth1085 Smalley, 2006, Life isn't flat: taking cancer biology to the next dimension, In Vitro Cell Dev Biol Anim, 42, 242, 10.1290/0604027.1 Kong, 2007, Microenvironmental regulation of biomacromolecular therapies, Nat Rev Drug Discov, 6, 455, 10.1038/nrd2309 Prestwich, 2008, Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery, Acc Chem Res, 41, 139, 10.1021/ar7000827 Sahoo, 2005, Characterization of porous PLGA/PLA microparticles as a scaffold for three dimensional growth of breast cancer cells, Biomacromolecules, 6, 1132, 10.1021/bm0492632 Doillon, 2004, Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity, Anticancer Res, 24, 2169 Debnath, 2005, Modelling glandular epithelial cancers in three-dimensional cultures, Nat Rev Cancer, 5, 675, 10.1038/nrc1695 Serebriiskii, 2008, Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells, Matrix Biol, 27, 573, 10.1016/j.matbio.2008.02.008 Kim, 2005, Three-dimensional tissue culture models in cancer biology, Semin Cancer Biol, 15, 365, 10.1016/j.semcancer.2005.05.002 Yamada, 2007, Modeling tissue morphogenesis and cancer in 3D, Cell, 130, 601, 10.1016/j.cell.2007.08.006 Clark, 1995, Biology of bone marrow stroma, Ann N Y Acad Sci, 770, 70, 10.1111/j.1749-6632.1995.tb31044.x Meyer, 1958, Chemical structure of hyaluronic acid, Fed Proc, 17, 1075 Schade, 2006, Hyaluronate and its receptors in bone marrow, Acta Histochem, 108, 141, 10.1016/j.acthis.2006.03.018 Bharadwaj, 2009, Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan synthesis and processing, Am J Pathol, 174, 1027, 10.2353/ajpath.2009.080501 Bourguignon, 2003, Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression, J Biol Chem, 278, 29420, 10.1074/jbc.M301885200 Bourguignon, 2002, Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells, J Biol Chem, 277, 39703, 10.1074/jbc.M204320200 Fujita, 2002, CD44 signaling through focal adhesion kinase and its anti-apoptotic effect, FEBS Lett, 528, 101, 10.1016/S0014-5793(02)03262-3 Toole, 2008, Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells, Semin Cancer Biol, 18, 244, 10.1016/j.semcancer.2008.03.009 Jia, 2004, Prolongation of sciatic nerve blockade by in situ cross-linked hyaluronic acid, Biomaterials, 25, 4797, 10.1016/j.biomaterials.2003.12.012 Jia, 2006, Hyaluronic acid-based microgels and microgel networks for vocal fold regeneration, Biomacromolecules, 7, 3336, 10.1021/bm0604956 Jha, 2009, Structural analysis and mechanical characterization of hyaluronic acid-based doubly cross-linked networks, Macromolecules, 42, 537, 10.1021/ma8019442 Liu, 2004, Steady-state fluorescence study on release of camptothecin from agar hydrogel, Int J Pharm, 287, 13, 10.1016/j.ijpharm.2004.08.010 Watanabe, 2008, In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin, J Control Release, 127, 231, 10.1016/j.jconrel.2008.02.005 Farokhzad, 2006, Targeted nanoparticle–aptamer bioconjugates for cancer chemotherapy in vivo, Proc Natl Acad Sci U S A, 103, 6315, 10.1073/pnas.0601755103 Phenomenex C, Usa. Curosil/Taxol: Columns for Taxane Analysis. David, 2008, Hyaluronan hydrogel: an appropriate three-dimensional model for evaluation of anticancer drug sensitivity, Acta Biomater, 4, 256, 10.1016/j.actbio.2007.08.012 Stern, 2007, The many ways to cleave hyaluronan, Biotechnol Adv, 25, 537, 10.1016/j.biotechadv.2007.07.001 Horning, 2008, 3-D tumor model for in vitro evaluation of anticancer drugs, Mol Pharmacol, 5, 849, 10.1021/mp800047v Gayet, 1996, High water content BSA–PEG hydrogel for controlled release device: evaluation of the drug release properties, J Control Release, 38, 177, 10.1016/0168-3659(95)00118-2 Nelson, 1999, Manipulation of the C(22)–C(27) region of rapamycin: stability issues and biological implications, Bioorg Med Chem Lett, 9, 295, 10.1016/S0960-894X(98)00735-5 Laplanche, 2007, Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake, J Pharmacokinet Pharmcodyn, 34, 373, 10.1007/s10928-007-9051-7 Opdenaker, 2009, Rapamycin selectively reduces the association of transcripts containing complex 5′ UTRs with ribosomes in C4-2B prostate cancer cells, J Cell Biochem, 107, 473, 10.1002/jcb.22145 Hicks, 2006, Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs, J Natl Cancer Inst, 98, 1118, 10.1093/jnci/djj306 Lin, 1999, The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells, Cancer Res, 59, 2891 Wozniak, 2004, Focal adhesion regulation of cell behavior, Biochim Biophys Acta, 1692, 103, 10.1016/j.bbamcr.2004.04.007 Morgan, 2008, RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid, Prostate, 68, 861, 10.1002/pros.20752